Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Large-cap public M&A is a hard business to break into, but Paul Hastings feels its build, along with the arrival of Schiele, ...

announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ: CERE) for violations of the securities laws and ...

announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for violations of the securities laws and ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

He recently served as Senior Vice President, Head of Global Regulatory and Access Solutions at Cerevel Therapeutics (Cerevel) ...

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

He recently served as Senior Vice President, Head of Global Regulatory and Access Solutions at Cerevel Therapeutics (Cerevel), where he supported its successful acquisition by AbbVie Inc. Prior to ...

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy ...

Emraclidine was an experimental treatment for schizophrenia and Alzheimer's that AbbVie obtained through its acquisition of Cerevel Therapeutics, along with other experimental drugs such as ...